{"changes":[{"companyHref":"/c/autoimmunitybiologicsolutions-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/2045812/000204581226000003/primary_doc.xml","domain":"autoimmunitybiologicsolutions.com","fact":"latest round","name":"Autoimmunity Biologic Solutions Inc.","new":{"amountUsd":3200000,"date":"2024-11-08","lead":null,"type":null},"old":{"amountUsd":3200000,"date":"2024-11-08","lead":null,"type":"seed"},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"autoimmunitybiologicsolutions-com","status":"sourced","url":"https://whoraisedwhat.com/c/autoimmunitybiologicsolutions-com"},{"companyHref":"/c/autoimmunitybiologicsolutions-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/2045812/000204581226000003/primary_doc.xml","domain":"autoimmunitybiologicsolutions.com","fact":"provenance:round","name":"Autoimmunity Biologic Solutions Inc.","new":{"publisher":"SEC EDGAR","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/2045812/000204581226000003/primary_doc.xml"},"old":{"publisher":"sec-edgar","status":"attributed","url":null},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"autoimmunitybiologicsolutions-com","status":"sourced","url":"https://whoraisedwhat.com/c/autoimmunitybiologicsolutions-com"}],"country":"US","description":"Clinical-stage biotech developing monoclonal antibodies that target soluble IL-7 receptor to dampen autoimmune amplification. Initial programs focus on genetically defined patients with multiple sclerosis and lupus nephritis. Selective sIL7R targeting aims to correct the immune defect rather than broadly suppress immunity.","domain":"autoimmunitybiologicsolutions.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotechnology","investors":[],"lat":29.758938,"lng":-95.367697,"location":"HOUSTON, TX","name":"Autoimmunity Biologic Solutions Inc.","rounds":[{"amountQuarantined":false,"amountUsd":3200000,"currency":"USD","date":"2024-11-08","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/2045812/000204581226000003/primary_doc.xml"},"status":"sourced","type":null,"url":"https://www.sec.gov/Archives/edgar/data/2045812/000204581226000003/primary_doc.xml"}],"slug":"autoimmunitybiologicsolutions-com","sources":[{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/2045812/000204581226000003/primary_doc.xml"},{"fact":"existence","publisher":"autoimmunitybiologicsolutions.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://autoimmunitybiologicsolutions.com"},{"fact":"description","publisher":"autoimmunitybiologicsolutions.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://autoimmunitybiologicsolutions.com"}],"stage":null,"techStack":[],"totalRaisedUsd":3200000,"updatedAt":"2026-05-07"}